HUMA - Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries | Benzinga
Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair, showing that the HAV had higher rates of patency and lower rates of amputation and infection than historic synthetic graft benchmarks.
Humacyte plans to file a Biologics License Application for vascular trauma with the FDA during Q4 of 2023.
The V005 trial was a single-arm study conducted in the U.S. and Israel in patients with arterial injuries resulting from gunshots, workplace injuries, car accidents, or ...